Anupam Rasayan India Limited , a leading specialty chemicals company, has reported exceptional financial results for the second quarter, showcasing robust growth across key metrics.

Strong Revenue Growth

The company delivered a stellar performance with consolidated revenue from operations of ₹731.40 crore in Q2, marking a remarkable 148.80% year-on-year growth and a 50.50% sequential increase. For the first half, consolidated revenue reached ₹1,217.20 crore, representing an impressive 122.10% year-on-year growth.

Segment-wise Performance

Life Science Related Specialty Chemicals continued to be the primary revenue driver, contributing 84% of total revenue in H1. Within this segment:

• The Pharma segment accounted for 23% and registered a strong 201% YoY growth during H1, driven by new product launches and scale-up of recently commercialized molecules.
• Performance Materials contributed 16% of total revenue in H1, with revenue growing by 306% YoY, supported by the ramp-up of newly launched polymer molecules.

Profitability and Margins

The company reported consolidated EBITDA margins of approximately 19.50% in Q2 and 25.50% for H1. These margins were slightly subdued due to some dispatches made from older inventory. Management expects margins to normalize from Q3 onwards as new contracts and pricing structures take effect.

Order Book and Future Outlook

Anupam Rasayan's order book remains healthy at around ₹14,646.00 crore, spread over 5-7 years. The company expects these orders to contribute approximately ₹450.00 crore in revenue. Management has guided for over 50% revenue growth, largely attributed to recovery in agrochemicals sales and growth in polymer and pharma segments.

Geographical Performance

The US market has shown phenomenal growth and continues to be a key growth driver for the company. Importantly, the majority of Anupam Rasayan's products fall under the exempt category for recently imposed US tariffs, ensuring that exports remain unaffected by cost pressures.

Working Capital Management

The company has made significant progress in optimizing its balance sheet and improving working capital efficiency:

Management expects to further reduce working capital days to approximately 200 in the near term.

Debt Reduction

With the receipt of ₹277.50 crore from warrants in July, the company used ₹175.00 crore towards repayment of term debt, resulting in a net debt of ₹730.00 crore at the consolidated level.

Anand Desai, Managing Director of Anupam Rasayan, commented on the results: "This quarter truly reflects the best of Anupam Rasayan—our agility, customer trust, and execution strength—supported by a favorable industry environment and renewed momentum across global markets."

The company's strong performance in Q2 positions it well for sustained growth and profitability in the coming periods, reflecting the resilience of its business model, strong customer relationships, and operational excellence.

Anupam Rasayan India Ltd , a leading specialty chemicals company, has reported a strong financial performance for the second quarter of the fiscal year 2025-26. The company's results showcase significant growth in revenue and profitability, despite a contraction in margins.

Revenue Soars

For the quarter ended September 30, 2025, Anupam Rasayan reported a consolidated revenue of ₹7,313.98 crore, marking a substantial increase of 148.8% compared to ₹2,939.62 crore in the same quarter of the previous year. This impressive top-line growth underscores the company's expanding market presence and strong demand for its specialty chemical products.

Profitability Surge

The company's bottom line saw a significant improvement:

• Net profit for Q2 FY2025-26 stood at ₹571.52 crore, up by 86.6% from ₹306.23 crore in Q2 FY2024-25.
• On a half-yearly basis, the net profit reached ₹1,056.10 crore, showing a remarkable growth of 146.6% compared to ₹428.34 crore in the corresponding period of the previous year.

EBITDA Performance

Anupam Rasayan's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the quarter increased to ₹1,358.89 crore, up from ₹804.05 crore in the same quarter last year, representing a growth of 68.9%.

Margin Pressure

Despite the strong revenue and profit growth, the company experienced some pressure on its margins:

• EBITDA margin for Q2 FY2025-26 contracted to 18.54% from 27.35% in Q2 FY2024-25.
• This margin contraction suggests that while the company has significantly expanded its operations, it may be facing some cost pressures or changes in product mix affecting overall profitability ratios.

Financial Position

As of September 30, 2025, Anupam Rasayan's balance sheet reflects a solid financial position:

• Total assets stood at ₹56,498.46 crore, up from ₹52,688.84 crore as of March 31, 2025.
• The company's equity base expanded to ₹31,972.88 crore, compared to ₹28,503.13 crore at the end of the previous fiscal year.

Capital Allocation

During the quarter, Anupam Rasayan made strategic moves to strengthen its capital structure:

• The company allotted 39,14,886 fully paid-up equity shares at an issue price of ₹945.11 per share through a preferential allotment.
• This move raised approximately ₹3,700 crore, of which ₹2,768.98 crore has been utilized for loan repayment and general corporate purposes.

Looking Ahead

As Anupam Rasayan continues to expand its operations and capitalize on the growing demand for specialty chemicals, managing costs and improving operational efficiency will be key focus areas to enhance profitability margins in the coming quarters.

The company's robust financial performance, coupled with its strategic capital raising, positions it well for future growth in the dynamic specialty chemicals sector.